Gubra (GUBRA) Partnership summary

Opening remarks and agenda

• Announcement of a transformative partnership and license agreement for GUBamy (GUB014295), an amylin analog for obesity, with participation from AbbVie and Gubra leadership.

• Conference call and analyst presentation held to discuss the agreement and strategic implications.

Objectives of the partnership

• Accelerate development and commercialization of GUBamy/GUB014295 for obesity by leveraging AbbVie's global infrastructure and resources.

• Address significant unmet needs in obesity care and foster long-term growth.

Partner introductions and roles

• AbbVie will lead global development and commercialization of GUBamy/GUB014295 after closing.

• Gubra provides discovery and early-stage development expertise, retaining eligibility for upfront, milestone, and royalty payments.